Vetoquinol SA
Closed
SectorHealthcare
68.5 -1.15
Overview
Share price change
24h
Min
68.2
Max
70.5
Income | 7.2M 32M |
|---|---|
Sales | 10M 268M |
P/E Sector Avg | 14.312 49.052 |
Dividend yield | 1.34 |
Profit margin | 12.043 |
Employees | 2,422 |
EBITDA | 252M 301M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +58.27% upside |
Dividend yield Sector Avg | 1.34% 2.36% |
|---|---|
Next Earnings | 11 wrz 2026 |
Market Cap | -113M 822M |
|---|---|
Previous open | 69.65 |
Previous close | 68.5 |
News Sentiment
By Acuity
50%
50%
162 / 342 Ranking in Healthcare
Vetoquinol SA Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
About Vetoquinol SA
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
